Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

被引：1
|
作者：
Tanvetyanon, T [1 ]
机构：
[1] Loyola Univ, Stritch Sch Med, Cardinal Bernardin Canc Inst, Maywood, IL 60153 USA
来源：
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2005年 / 97卷 / 01期
关键词：
D O I：
10.1093/jnci/dji016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer
    Reed, SD
    Radeva, JI
    Glendenning, GA
    Saad, F
    Schulman, KA
    JOURNAL OF UROLOGY, 2004, 171 (04): : 1537 - 1542
  • [32] Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
    Hortobagyi, GN
    Theriault, RL
    Lipton, A
    Porter, L
    Blayney, D
    Sinoff, C
    Wheeler, H
    Simeone, JF
    Seaman, JJ
    Knight, RD
    Heffernan, M
    Mellars, K
    Reitsma, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) : 2038 - 2044
  • [33] Docetaxel, vinorelbine and zoledronic acid as first-line treatment in patients with hormone-refractory prostate cancer
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 95 - 95
  • [34] The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid
    Oh, William K.
    Proctor, Kevin
    Nakabayashi, Mari
    Evan, Carolyn
    Tormey, Lauren K.
    Daskivich, Timothy
    Antras, Lucia
    Smith, Michael
    Neary, Maureen P.
    Duh, Mei Sheng
    CANCER, 2007, 109 (06) : 1090 - 1096
  • [35] Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
    Rader, Michael
    Goessl, Carsten
    Cong, Ze
    JOURNAL OF MANAGED CARE PHARMACY, 2012, 18 (01): : 74 - 75
  • [36] Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
    Xie, Jipan
    Namjoshi, Madhav
    Wu, Eric Q.
    Parikh, Kejal
    Diener, Melissa
    Yu, Andrew P.
    Guo, Amy
    Culver, Kenneth W.
    JOURNAL OF MANAGED CARE PHARMACY, 2011, 17 (08): : 621 - 634
  • [37] Survival benefit during zoledronic acid and docetaxel-based chemotherapy in metastatic hormone-refractory prostate cancer patients: an institutional report
    Samelis, G. F.
    Ekmektzoglou, K. A.
    Tsiakou, A.
    Giannakaki, S.
    Georgoulias, D.
    Christophilopoulos, K.
    JOURNAL OF BUON, 2011, 16 (04): : 738 - 743
  • [38] Clinical benefit of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer based on history of skeletal complications.
    Chin, JL
    Saad, F
    Gleason, DM
    Murray, R
    Tchekmedyian, S
    Venner, P
    Lacombe, L
    Vinholes, JJ
    Zheng, M
    Hei, YJJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 400S - 400S
  • [39] Normalization of serum PSA level using zoledronic acid on metastatic hormone-refractory prostate cancer resistant to estramustine and betamethasone
    Seike, Kensaku
    Asaeda, Yukiko
    Yamamoto, Naoki
    Maeda, Shinichi
    CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2009, 62 (02) : 114 - 115
  • [40] Clinical benefit of zoledronic acid for the prevention of multiple skeletal complications in patients with prostate cancer based on history of skeletal complications
    Murray, Robin
    Chin, Joseph L.
    Saad, Fred
    Gleason, Donald M.
    Tchekmedyian, N. Simon
    Lacombe, Louis
    Vinholes, Jeferson J.
    Zheng, Ming
    Hei, Yong-Jiang
    ANNALS OF ONCOLOGY, 2004, 15 : 116 - 116
12345